{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:55:44Z","timestamp":1792803344865,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00284-025-04655-7","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T07:27:02Z","timestamp":1765265222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bedaquiline Resistance: A Looming Global Threat in Tuberculosis Management"],"prefix":"10.1007","volume":"83","author":[{"given":"Indu","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8735-5562","authenticated-orcid":false,"given":"Divakar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Ratn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megh Singh","family":"Dhakad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasbir","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza Masroor Ali","family":"Beg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"10","key":"4655_CR1","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/cid\/cix992","volume":"66","author":"TV Nguyen","year":"2018","unstructured":"Nguyen TV, Anthony RM, Ba\u00f1uls AL, Nguyen TV, Vu DH, Alffenaar JW (2018) Bedaquiline resistance: its emergence, mechanism, and prevention. Clin Infect Dis 66(10):1625\u20131630. https:\/\/doi.org\/10.1093\/cid\/cix992","journal-title":"Clin Infect Dis"},{"key":"4655_CR2","unstructured":"WHO (2023) (https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis)"},{"issue":"4","key":"4655_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf068","volume":"81","author":"R Singla","year":"2025","unstructured":"Singla R, Khan S, Silsarma A, Chavan V, Mahajan R, Mansoor H, Devan RK, Singla N, Bhalla M, Kumar G, Singh P (2025) Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: a multicentric retrospective cohort study. Clin Infect Dis ciaf068. https:\/\/doi.org\/10.1093\/cid\/ciaf068","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4655_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1473-3099(23)00498-X","volume":"1","author":"I Barilar","year":"2024","unstructured":"Barilar I, Fernando T, Utpatel C, Abujate C, Madeira CM, Jos\u00e9 B, Mutaquiha C, Kranzer K, Niemann T, Ismael N, de Araujo L (2024) Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB\/RIF in Mozambique: a retrospective observational study. Lancet Infect Dis 1(3):297\u2013307. https:\/\/doi.org\/10.1016\/S1473-3099(23)00498-X","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"4655_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.tube.2014.04.001","volume":"94","author":"AK Kakkar","year":"2014","unstructured":"Kakkar AK, Dahiya N (2014) Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis 94(4):357\u2013. https:\/\/doi.org\/10.1016\/j.tube.2014.04.001. 62","journal-title":"Tuberculosis"},{"key":"4655_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00639-2023","author":"R Perumal","year":"2023","unstructured":"Perumal R, Bionghi N, Nimmo C, Letsoalo M, Cummings MJ, Hopson M, Wolf A, Al Jubaer S, Padayatchi N, Naidoo K, Larsen MH (2023) Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.00639-2023","journal-title":"Eur Respir J"},{"issue":"9","key":"4655_CR7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/s2213-2600(18)30235-2","volume":"6","author":"K Schnippel","year":"2018","unstructured":"Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, Hughes J, Ferreira H, Padanilam X, Romero R, Te Riele J (2018) Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med 6(9):699\u2013706. https:\/\/doi.org\/10.1016\/s2213-2600(18)30235-2","journal-title":"Lancet Respir Med"},{"key":"4655_CR8","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"N Cocco","year":"2019","unstructured":"Cocco N, Gargioni G, Gilpin C, Gonzalez-Angulo L, Grzemska M, Korobitsyn A, Merle C, Mirzayev F, Moja L, Olliaro PL, Reis AA (2019) WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization"},{"issue":"8","key":"4655_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/nejmoa1313865","volume":"21","author":"AH Diacon","year":"2014","unstructured":"Diacon AH, Pym A, Grobusch MP, de Los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M (2014) Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 21(8):723\u201332. https:\/\/doi.org\/10.1056\/nejmoa1313865","journal-title":"N Engl J Med"},{"issue":"12","key":"4655_CR10","doi-asserted-by":"publisher","first-page":"e972","DOI":"10.1016\/s2666-5247(23)00172-6","volume":"1","author":"B Derendinger","year":"2023","unstructured":"Derendinger B, Dippenaar A, de Vos M, Huo S, Alberts R, Tadokera R, Limberis J, Sirgel F, Dolby T, Spies C, Reuter A (2023) Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study. The Lancet Microbe 1(12):e972-82. https:\/\/doi.org\/10.1016\/s2666-5247(23)00172-6","journal-title":"The Lancet Microbe"},{"issue":"1","key":"4655_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jobb.2024.01.001","volume":"6","author":"P Satapathy","year":"2024","unstructured":"Satapathy P, Itumalla R, Neyazi A, Taraki AM, Khatib MN, Gaidhane S, Zahiruddin QS, Rustagi S, Neyazi M (2024) Emerging bedaquiline resistance: a threat to the global fight against drug-resistant tuberculosis. J Biosaf Biosecur 6(1):13\u201315. https:\/\/doi.org\/10.1016\/j.jobb.2024.01.001","journal-title":"J Biosaf Biosecur"},{"issue":"2","key":"4655_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac029","volume":"1","author":"JS Mallick","year":"2022","unstructured":"Mallick JS, Nair P, Abbew ET, Van Deun A, Decroo T (2022) Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. JAC-antimicrobial resistance 1(2):dlac029. https:\/\/doi.org\/10.1093\/jacamr\/dlac029","journal-title":"JAC-antimicrobial resistance"},{"key":"4655_CR13","doi-asserted-by":"publisher","first-page":"100405","DOI":"10.1016\/j.jctube.2023.100405","volume":"34","author":"OU Rehman","year":"2024","unstructured":"Rehman OU, Fatima E, Ali A, Akram U, Nashwan A, Yunus F (2024) Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: an updated systematic review and meta-analysis. J Clin Tuberculosis Other Mycobact Dis 34:100405. https:\/\/doi.org\/10.1016\/j.jctube.2023.100405","journal-title":"J Clin Tuberculosis Other Mycobact Dis"},{"issue":"5","key":"4655_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1517\/17425255.2016.1162785","volume":"12","author":"MA Zuur","year":"2016","unstructured":"Zuur MA, Bolhuis MS, Anthony R, den Hertog A, van der Laan T, Wilffert B, de Lange W, van Soolingen D, Alffenaar JW (2016) Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. Expert Opin Drug Metab Toxicol 12(5):509\u2013521. https:\/\/doi.org\/10.1517\/17425255.2016.1162785","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4655_CR15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01719-2016","author":"N Veziris","year":"2017","unstructured":"Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M, Caumes E, Lerat I, Rioux C, Yazdanpanah Y, Tiotiu A (2017) Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01719-2016","journal-title":"Eur Respir J"},{"issue":"1","key":"4655_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1186\/s12879-025-11067-2","volume":"25","author":"X Hu","year":"2025","unstructured":"Hu X, Wu Z, Lei J, Zhu Y, Gao J (2025) Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 25(1):689. https:\/\/doi.org\/10.1186\/s12879-025-11067-2","journal-title":"BMC Infect Dis"},{"issue":"12","key":"4655_CR17","doi-asserted-by":"publisher","first-page":"e964","DOI":"10.1016\/s2666-5247(23)00321-x","volume":"4","author":"C Lange","year":"2023","unstructured":"Lange C, Vasiliu A, Mandalakas AM (2023) Emerging bedaquiline-resistant tuberculosis. Lancet Microbe 4(12):e964\u2013e965. https:\/\/doi.org\/10.1016\/s2666-5247(23)00321-x","journal-title":"Lancet Microbe"},{"key":"4655_CR18","unstructured":"World Health Organization Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789241548809. Accessed 29 January 2017"},{"issue":"9","key":"4655_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1164\/rccm.201605-1065le","volume":"194","author":"H Hoffmann","year":"2016","unstructured":"Hoffmann H, Hofmann-Thiel S, Merker M, Kohl TA, Niemann S (2016) Reply: call for regular susceptibility testing of bedaquiline and delamanid. Am J Respir Crit Care Med 194(9):1171\u20131172. https:\/\/doi.org\/10.1164\/rccm.201605-1065le","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"4655_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bcp.12613","volume":"80","author":"SC Goulooze","year":"2015","unstructured":"Goulooze SC, Cohen AF, Rissmann R, Bedaquiline (2015) Br J Clin Pharmacol 80(2):182. https:\/\/doi.org\/10.1111\/bcp.12613","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4655_CR21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.2217\/fmb.10.50","volume":"5","author":"A Matteelli","year":"2010","unstructured":"Matteelli A, Carvalho AC, Dooley KE, Kritski A (2010) TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 5(6):849\u2013858. https:\/\/doi.org\/10.2217\/fmb.10.50","journal-title":"Future Microbiol"},{"key":"4655_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jgar.2021.02.017","volume":"25","author":"S Khoshnood","year":"2021","unstructured":"Khoshnood S, Goudarzi M, Taki E, Darbandi A, Kouhsari E, Heidary M, Motahar M, Moradi M, Bazyar H (2021) Bedaquiline: current status and future perspectives. J Glob Antimicrob Resist 25:48\u201359. https:\/\/doi.org\/10.1016\/j.jgar.2021.02.017","journal-title":"J Glob Antimicrob Resist"},{"key":"4655_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/cmdc.201600441","volume":"12","author":"C He","year":"2017","unstructured":"He C, Preiss L, Wang B, Fu L, Wen H, Zhang X, Cui H, Meier T, Yin D (2017) Structural simplification of bedaquiline: the discovery of 3-(4\u2010(N, N\u2010Dimethylaminomethyl) phenyl) quinoline\u2010derived antitubercular lead compounds. ChemMedChem 12:106\u201319. https:\/\/doi.org\/10.1002\/cmdc.201600441","journal-title":"ChemMedChem"},{"issue":"7","key":"4655_CR24","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/s0968-0896(02)00071-8","volume":"10","author":"L Savini","year":"2002","unstructured":"Savini L, Chiasserini L, Gaeta A, Pellerano C (2002) Synthesis and anti-tubercular evaluation of 4-quinolylhydrazones. Bioorg Med Chem 10(7):2193\u20132198. https:\/\/doi.org\/10.1016\/s0968-0896(02)00071-8","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"4655_CR25","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1128\/aac.44.4.848-852.2000","volume":"44","author":"CM Kunin","year":"2000","unstructured":"Kunin CM, Ellis WY (2000) Antimicrobial activities of mefloquine and a series of related compounds. Antimicrob Agents Chemother 44(4):848\u2013. https:\/\/doi.org\/10.1128\/aac.44.4.848-852.2000. 52","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"4655_CR26","doi-asserted-by":"publisher","first-page":"6977","DOI":"10.1128\/aac.01291-16","volume":"60","author":"S Kundu","year":"2016","unstructured":"Kundu S, Biukovic G, Gr\u00fcber G, Dick T (2016) Bedaquiline targets the \u03b5 subunit of mycobacterial F-ATP synthase. Antimicrob Agents Chemother 60(11):6977\u20136979. https:\/\/doi.org\/10.1128\/aac.01291-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"4655_CR27","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1099\/jmm.0.000537","volume":"66","author":"DA Aguilar-Ayala","year":"2017","unstructured":"Aguilar-Ayala DA, Cnockaert M, Andr\u00e9 E, Andries K, Gonzalez-Y-Merchand JA, Vandamme P, Palomino JC, Martin A (2017) In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. J Med Microbiol 66(8):1140\u20131143. https:\/\/doi.org\/10.1099\/jmm.0.000537","journal-title":"J Med Microbiol"},{"issue":"7","key":"4655_CR28","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1093\/jac\/dkv054","volume":"70","author":"K Hards","year":"2015","unstructured":"Hards K, Robson JR, Berney M, Shaw L, Bald D, Koul A, Andries K, Cook GM (2015) Bactericidal mode of action of bedaquiline. J Antimicrob Chemother 70(7):2028\u20132037. https:\/\/doi.org\/10.1093\/jac\/dkv054","journal-title":"J Antimicrob Chemother"},{"key":"4655_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.tube.2017.12.002","volume":"109","author":"V Lohrasbi","year":"2018","unstructured":"Lohrasbi V, Talebi M, Bialvaei AZ, Fattorini L, Drancourt M, Heidary M, Darban-Sarokhalil D (2018) Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance. Tuberculosis 109:17\u201327. https:\/\/doi.org\/10.1016\/j.tube.2017.12.002","journal-title":"Tuberculosis"},{"issue":"29","key":"4655_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1126\/science.1111199","volume":"308","author":"T Meier","year":"2005","unstructured":"Meier T, Polzer P, Diederichs K, Welte W, Dimroth P (2005) Structure of the rotor ring of F-Type Na+-ATPase from Ilyobactertartaricus. Science 308(29):659\u201362. https:\/\/doi.org\/10.1126\/science.1111199","journal-title":"Science"},{"issue":"2","key":"4655_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw426","volume":"72","author":"MC Cholo","year":"2016","unstructured":"Cholo MC, Mothiba MT, Fourie B, Anderson R (2016) Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. J Antimicrob Chemother (2):dkw426. https:\/\/doi.org\/10.1093\/jac\/dkw426","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4655_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/1060028013504087","volume":"48","author":"EB Chahine","year":"2014","unstructured":"Chahine EB, Karaoui LR, Mansour H (2014) Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother 48(1):107\u2013115. https:\/\/doi.org\/10.1177\/1060028013504087","journal-title":"Ann Pharmacother"},{"issue":"2","key":"4655_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1378\/chest.14-2764","volume":"148","author":"JV Philley","year":"2015","unstructured":"Philley JV, Wallace RJ Jr, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, Aksamit TR, Griffith DE (2015) Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest 148(2):499\u2013506. https:\/\/doi.org\/10.1378\/chest.14-2764","journal-title":"Chest"},{"issue":"10","key":"4655_CR34","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1128\/AAC.00803-15","volume":"59","author":"B Gold","year":"2015","unstructured":"Gold B, Roberts J, Ling Y, Quezada LL, Glasheen J, Ballinger E, Somersan-Karakaya S, Warrier T, Warren JD, Nathan C (2015) Rapid, semiquantitative assay to discriminate among compounds with activity against replicating or nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 59(10):6521\u20136538. https:\/\/doi.org\/10.1128\/AAC.00803-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"4655_CR35","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1111\/bcp.14357","volume":"86","author":"B Kamel","year":"2020","unstructured":"Kamel B, Graham GG, Stocker SL, Liu Z, Williams KM, Carland JE, Pile KD, Day RO (2020) A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects. Br J Clin Pharmacol 86(12):2486\u20132496. https:\/\/doi.org\/10.1111\/bcp.14357","journal-title":"Br J Clin Pharmacol"},{"key":"4655_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40121-013-0009-3","volume":"2","author":"GJ Fox","year":"2013","unstructured":"Fox GJ, Menzies D (2013) A review of the evidence for using bedaquiline (TMC207) to treat multidrug-resistant tuberculosis. Infect Dis Ther 2:123\u2013144. https:\/\/doi.org\/10.1007\/s40121-013-0009-3","journal-title":"Infect Dis Ther"},{"issue":"8","key":"4655_CR37","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2016\/19052.8286","volume":"10","author":"S Yadav","year":"2016","unstructured":"Yadav S, Rawal G, Baxi M (2016) Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Journal of Clinical and Diagnostic Research: JCDR 10(8):FM01. https:\/\/doi.org\/10.7860\/JCDR\/2016\/19052.8286","journal-title":"Journal of Clinical and Diagnostic Research: JCDR"},{"issue":"12","key":"4655_CR38","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.5588\/ijtld.16.0065","volume":"20","author":"K Dheda","year":"2016","unstructured":"Dheda K, Esmail A, Limberis J, Maartens G (2016) Selected questions and controversies about bedaquiline: a view from the field. Int J Tuberc Lung Dis 20(12):S24\u201332. https:\/\/doi.org\/10.5588\/ijtld.16.0065","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"4655_CR39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.tube.2010.07.004","volume":"90","author":"J Dhillon","year":"2010","unstructured":"Dhillon J, Andries K, Phillips PP, Mitchison DA (2010) Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis 90(5):301\u2013305. https:\/\/doi.org\/10.1016\/j.tube.2010.07.004","journal-title":"Tuberculosis"},{"issue":"9","key":"4655_CR40","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1093\/jac\/dku171","volume":"69","author":"RP Van Heeswijk","year":"2014","unstructured":"Van Heeswijk RP, Dannemann B, Hoetelmans RM (2014) Bedaquiline: a review of human pharmacokinetics and drug\u2013drug interactions. J Antimicrob Chemother 69(9):2310\u20138. https:\/\/doi.org\/10.1093\/jac\/dku171","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"4655_CR41","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1128\/aac.01418-13","volume":"58","author":"SC McLeay","year":"2014","unstructured":"McLeay SC, Vis P, Van Heeswijk RP, Green B (2014) Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother 58(9):5315\u201324. https:\/\/doi.org\/10.1128\/aac.01418-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4655_CR42","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1283105","volume":"5","author":"LR Codecasa","year":"2017","unstructured":"Codecasa LR, Toumi M, D\u2019Ausilio A, Aiello A, Damele F, Termini R, Uglietti A, Hettle R, Graziano G, De Lorenzo S (2017) Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy. Journal of market access & health policy 5(1):1283105. https:\/\/doi.org\/10.1080\/20016689.2017.1283105","journal-title":"Journal of market access & health policy"},{"issue":"8","key":"4655_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001300","volume":"9","author":"SD Ahuja","year":"2012","unstructured":"Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED (2012) Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med e1001300. https:\/\/doi.org\/10.1371\/journal.pmed.1001300","journal-title":"PLoS Med"},{"key":"4655_CR44","doi-asserted-by":"publisher","unstructured":"Brigden G, Hewison C, Varaine F (2015) New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infection and drug resistance. 30:367\u2013378. https:\/\/doi.org\/10.2147\/idr.s68351","DOI":"10.2147\/idr.s68351"},{"issue":"23","key":"4655_CR45","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/nejmoa0808427","volume":"360","author":"AH Diacon","year":"2009","unstructured":"Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360(23):2397\u20132405. https:\/\/doi.org\/10.1056\/nejmoa0808427","journal-title":"N Engl J Med"},{"issue":"2","key":"4655_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/cid\/ciu786","volume":"60","author":"L Guglielmetti","year":"2015","unstructured":"Guglielmetti L, Le D\u00fb D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, M\u00e9tivier N, Robert J (2015) Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 60(2):188\u201394. https:\/\/doi.org\/10.1093\/cid\/ciu786","journal-title":"Clin Infect Dis"},{"issue":"10","key":"4655_CR47","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1080\/14740338.2019.1648429","volume":"18","author":"K Cohen","year":"2019","unstructured":"Cohen K, Maartens G (2019) A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis. Expert Opin Drug Saf 18(10):875\u2013882. https:\/\/doi.org\/10.1080\/14740338.2019.1648429","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"4655_CR48","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1183\/13993003.01891-2015","volume":"47","author":"E Pontali","year":"2016","unstructured":"Pontali E, Sotgiu G, D\u2019Ambrosio L, Centis R, Migliori GB (2016) Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 47(2):394\u2013402. https:\/\/doi.org\/10.1183\/13993003.01891-2015","journal-title":"Eur Respir J"},{"key":"4655_CR49","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01799-2016","author":"L Guglielmetti","year":"2017","unstructured":"Guglielmetti L, Jaspard M, Le D\u00fb D, Lach\u00e2tre M, Marigot-Outtandy D, Bernard C, Veziris N, Robert J, Yazdanpanah Y, Caumes E, Fr\u00e9chet-Jachym M (2017) Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01799-2016","journal-title":"Eur Respir J"},{"issue":"5707","key":"4655_CR50","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries K, Verhasselt P, Guillemont J, G\u00f6hlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707):223\u2013227. https:\/\/doi.org\/10.1126\/science.1106753","journal-title":"Science"},{"issue":"3","key":"4655_CR51","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1128\/aac.01611-09","volume":"54","author":"E Huitric","year":"2010","unstructured":"Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI (2010) Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 54(3):1022\u20131028. https:\/\/doi.org\/10.1128\/aac.01611-09","journal-title":"Antimicrob Agents Chemother"},{"key":"4655_CR52","volume-title":"Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention (2013) Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. CDC, Atlanta, GA. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6209a1.htm"},{"issue":"2","key":"4655_CR53","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1183\/13993003.00724-2015","volume":"47","author":"AS Pym","year":"2016","unstructured":"Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M (2016) Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis. Eur Respir J 47(2):564\u2013574. https:\/\/doi.org\/10.1183\/13993003.00724-2015","journal-title":"Eur Respir J"},{"issue":"2","key":"4655_CR54","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1183\/09031936.00142914","volume":"45","author":"A Somoskovi","year":"2015","unstructured":"Somoskovi A, Bruderer V, H\u00f6mke R, Bloemberg GV, B\u00f6ttger EC (2015) A mutation associated with Clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 45(2):554\u2013557. https:\/\/doi.org\/10.1183\/09031936.00142914","journal-title":"Eur Respir J"},{"issue":"6","key":"4655_CR55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00239-17","volume":"61","author":"J Xu","year":"2017","unstructured":"Xu J, Wang B, Hu M, Huo F, Guo S, Jing W, Nuermberger E, Lu Y (2017) Primary Clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 61(6):10\u2013128. https:\/\/doi.org\/10.1128\/AAC.00239-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"4655_CR56","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jac\/dkw502","volume":"72","author":"C Villellas","year":"2017","unstructured":"Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, Andries K (2017) Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of Clofazimine or bedaquiline. J Antimicrob Chemother 72(3):684\u2013690. https:\/\/doi.org\/10.1093\/jac\/dkw502","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"4655_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/aac.02530-18","volume":"63","author":"H Ghajavand","year":"2019","unstructured":"Ghajavand H, KargarpourKamakoli M, Khanipour S, PourazarDizaji S, Masoumi M, RahimiJamnani F, Fateh A, Siadat SD, Vaziri F (2019) High prevalence of bedaquiline resistance in treatment-naive tuberculosis patients and verapamil effectiveness. Antimicrob Agents Chemother 63(3):10\u2013128. https:\/\/doi.org\/10.1128\/aac.02530-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"4655_CR58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/aac.00915-19","volume":"63","author":"A Ghodousi","year":"2019","unstructured":"Ghodousi A, Rizvi AH, Baloch AQ, Ghafoor A, Khanzada FM, Qadir M, Borroni E, Trovato A, Tahseen S, Cirillo DM (2019) Acquisition of cross-resistance to bedaquiline and Clofazimine following treatment for tuberculosis in Pakistan. Antimicrob Agents Chemother 63(9):10\u2013128. https:\/\/doi.org\/10.1128\/aac.00915-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"4655_CR59","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/jac\/dkx094","volume":"72","author":"DV Zimenkov","year":"2017","unstructured":"Zimenkov DV, Nosova EY, Kulagina EV, Antonova OV, Arslanbaeva LR, Isakova AI, Krylova LY, Peretokina IV, Makarova MV, Safonova SG, Borisov SE (2017) Examination of bedaquiline-and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother 72(7):1901\u20131906. https:\/\/doi.org\/10.1093\/jac\/dkx094","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"4655_CR60","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/2040622315582325","volume":"6","author":"SK Field","year":"2015","unstructured":"Field SK (2015) Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis 6(4):170\u2013184. https:\/\/doi.org\/10.1177\/2040622315582325","journal-title":"Ther Adv Chronic Dis"},{"key":"4655_CR61","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fcimb.2018.00114","volume":"8","author":"HA Hameed","year":"2018","unstructured":"Hameed HA, Islam MM, Chhotaray C, Wang C, Liu Y, Tan Y, Li X, Tan S, Delorme V, Yew WW, Liu J (2018) Molecular targets related drug resistance mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis strains. Front Cell Infect Microbiol 8:114. https:\/\/doi.org\/10.3389\/fcimb.2018.00114","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"4655_CR62","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1128\/aac.00753-16","volume":"60","author":"D Almeida","year":"2016","unstructured":"Almeida D, Ioerger T, Tyagi S, Li SY, Mdluli K, Andries K, Grosset J, Sacchettini J, Nuermberger E (2016) Mutations in PepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother 60(8):4590\u20134599. https:\/\/doi.org\/10.1128\/aac.00753-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4655_CR63","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1128\/JCM.02087-16","volume":"55","author":"DC Alexander","year":"2017","unstructured":"Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA, Perry BJ, Griffith DE, Benwill JL, Cameron AD, Wallace Jr RJ (2017) Emergence of mmpT5 variants during bedaquiline treatment of Mycobacterium intracellulare lung disease. J Clin Microbiol 55(2):574\u201384. https:\/\/doi.org\/10.1128\/JCM.02087-16","journal-title":"J Clin Microbiol"},{"issue":"3","key":"4655_CR64","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1164\/rccm.201502-0372le","volume":"193","author":"H Hoffmann","year":"2016","unstructured":"Hoffmann H, Kohl TA, Hofmann-Thiel S, Merker M, Beckert P, Jaton K, Nedialkova L, Sahalchyk E, Rothe T, Keller PM, Niemann S (2016) Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee. Am J Respir Crit Care Med 193(3):337\u2013340. https:\/\/doi.org\/10.1164\/rccm.201502-0372le","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"4655_CR65","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1128\/AAC.06154-11","volume":"56","author":"E Segala","year":"2012","unstructured":"Segala E, Sougakoff W, Nevejans-Chauffour A, Jarlier V, Petrella S (2012) New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother 56(5):2326\u20132334. https:\/\/doi.org\/10.1128\/AAC.06154-11","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"4655_CR66","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1128\/AAC.00181-07","volume":"51","author":"E Huitric","year":"2007","unstructured":"Huitric E, Verhasselt P, Andries K, Hoffner SE (2007) In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 51(11):4202\u20134204. https:\/\/doi.org\/10.1128\/AAC.00181-07","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"4655_CR67","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/17512433.2016.1200462","volume":"9","author":"TV Nguyen","year":"2016","unstructured":"Nguyen TV, Cao TB, Akkerman OW, Tiberi S, Vu DH, Alffenaar JW (2016) Bedaquiline as part of combination therapy in adults with pulmonary multidrug-resistant tuberculosis. Expert Rev Clin Pharmacol 9(8):1025\u20131037. https:\/\/doi.org\/10.1080\/17512433.2016.1200462","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"4655_CR68","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1128\/AAC.01462-13","volume":"58","author":"S Gupta","year":"2014","unstructured":"Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR (2014) Efflux Inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58(1):574\u2013576. https:\/\/doi.org\/10.1128\/AAC.01462-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4655_CR69","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1128\/cmr.00117-14","volume":"28","author":"XZ Li","year":"2015","unstructured":"Li XZ, Pl\u00e9siat P, Nikaido H (2015) The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev 28(2):337\u2013418. https:\/\/doi.org\/10.1128\/cmr.00117-14","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"4655_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jac\/dkv316","volume":"71","author":"CM Pule","year":"2016","unstructured":"Pule CM, Sampson SL, Warren RM, Black PA, van Helden PD, Victor TC, Louw GE (2016) Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother 71(1):17\u201326. https:\/\/doi.org\/10.1093\/jac\/dkv316","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"4655_CR71","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1128\/aac.00037-14","volume":"58","author":"RC Hartkoorn","year":"2014","unstructured":"Hartkoorn RC, Uplekar S, Cole ST (2014) Cross-resistance between Clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58(5):2979\u20132981. https:\/\/doi.org\/10.1128\/aac.00037-14","journal-title":"Antimicrob Agents Chemother"},{"key":"4655_CR72","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw502","volume":"19","author":"N Coeck","year":"2015","unstructured":"Coeck N, Villelas C, Meehan C, Lounis N, Niemann S, Rigouts L, de Jong B, Andries K (2015) Unexpected high frequency of Rv0678 mutations in MDR-TB patients without documented prior use of clofazimine or bedaquiline. Int J Tuberc Lung Dis 19:S45. https:\/\/doi.org\/10.1093\/jac\/dkw502","journal-title":"Int J Tuberc Lung Dis"},{"issue":"7","key":"4655_CR73","doi-asserted-by":"publisher","first-page":"e102135","DOI":"10.1371\/journal.pone.0102135","volume":"9","author":"K Andries","year":"2014","unstructured":"Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A (2014) Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 9(7):e102135. https:\/\/doi.org\/10.1371\/journal.pone.0102135","journal-title":"PLoS One"},{"issue":"20","key":"4655_CR74","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1056\/nejmc1505196","volume":"373","author":"GV Bloemberg","year":"2015","unstructured":"Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, H\u00f6mke R, Ritter C, Feldmann J (2015) Acquired resistance to bedaquiline and Delamanid in therapy for tuberculosis. N Engl J Med 373(20):1986\u20131988. https:\/\/doi.org\/10.1056\/nejmc1505196","journal-title":"N Engl J Med"},{"issue":"1","key":"4655_CR75","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1046\/j.1365-2958.2003.03425.x","volume":"48","author":"CM Sassetti","year":"2003","unstructured":"Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high-density mutagenesis. Mol Microbiol 48(1):77\u201384. https:\/\/doi.org\/10.1046\/j.1365-2958.2003.03425.x","journal-title":"Mol Microbiol"},{"issue":"1","key":"4655_CR76","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2178243","volume":"12","author":"SB Georghiou","year":"2023","unstructured":"Georghiou SB, de Vos M, Velen K, Miotto P, Colman RE, Cirillo DM, Ismail N, Rodwell TC, Suresh A, Ruhwald M (2023) Designing molecular diagnostics for current tuberculosis drug regimens. Emerging microbes & infections 12(1):2178243. https:\/\/doi.org\/10.1080\/22221751.2023.2178243","journal-title":"Emerging microbes & infections"},{"key":"4655_CR77","unstructured":"World Health Organization. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. World Health Organization (2018) (https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-TB-2018.5)"},{"issue":"11","key":"4655_CR78","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.cmi.2020.07.037","volume":"26","author":"T Sch\u00f6n","year":"2020","unstructured":"Sch\u00f6n T, K\u00f6ser CU, Werngren J, Viveiros M, Georghiou S, Kahlmeter G, Giske C, Maurer F, Lina G, Turnidge J, van Ingen J (2020) What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex? Clin Microbiol Infect 26(11):1453\u20135. https:\/\/doi.org\/10.1016\/j.cmi.2020.07.037","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"4655_CR79","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S2666-5247(20)30031-8","volume":"1","author":"C Nimmo","year":"2020","unstructured":"Nimmo C, Millard J, van Dorp L, Brien K, Moodley S, Wolf A, Grant AD, Padayatchi N, Pym AS, Balloux F, O\u2019Donnell M (2020) Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. The Lancet Microbe 1(4):e165-74. https:\/\/doi.org\/10.1016\/S2666-5247(20)30031-8","journal-title":"The Lancet Microbe"},{"issue":"5","key":"4655_CR80","doi-asserted-by":"publisher","first-page":"e0176522","DOI":"10.1371\/journal.pone.0176522","volume":"12","author":"DJ Operario","year":"2017","unstructured":"Operario DJ, Koeppel AF, Turner SD, Bao Y, Pholwat S, Banu S, Foongladda S, Mpagama S, Gratz J, Ogarkov O, Zhadova S (2017) Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis. PLoS One 12(5):e0176522. https:\/\/doi.org\/10.1371\/journal.pone.0176522","journal-title":"PLoS One"},{"issue":"9","key":"4655_CR81","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.cmi.2024.03.009","volume":"30","author":"G G\u00fcnther","year":"2024","unstructured":"G\u00fcnther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C, Tuberculosis Network European Trials group (2024) Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL (M)) regimen for rifampicin-resistant tuberculosis in Europe. Clin Microbiol Infect 30(9):1197-e1. https:\/\/doi.org\/10.1016\/j.cmi.2024.03.009","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"4655_CR82","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jinf.2023.01.039","volume":"86","author":"N Koehler","year":"2023","unstructured":"Koehler N, Andres S, Merker M, Dreyer V, John A, Kuhns M, Krieger D, Choong E, Verougstraete N, ZurWiesch PA, Wicha SG (2023) Pretomanid-resistant tuberculosis. J Infect 86(5):520\u2013524. https:\/\/doi.org\/10.1016\/j.jinf.2023.01.039","journal-title":"J Infect"},{"issue":"3","key":"4655_CR83","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00052-23","volume":"67","author":"DV Almeida","year":"2023","unstructured":"Almeida DV, Converse PJ, Nuermberger EL (2023) Mutations in Rv0678 reduce susceptibility of Mycobacterium tuberculosis to the DprE1 inhibitor TBA-7371. Antimicrob Agents Chemother 67(3):e00052-23. https:\/\/doi.org\/10.1128\/aac.00052-23","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"4655_CR84","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00904-22","volume":"66","author":"NC Poulton","year":"2022","unstructured":"Poulton NC, Azadian ZA, DeJesus MA, Rock JM (2022) Mutations in rv0678 confer low-level resistance to benzothiazinone DprE1 inhibitors in Mycobacterium tuberculosis. Antimicrob Agents Chemother 66(9):e00904-22. https:\/\/doi.org\/10.1128\/aac.00904-22","journal-title":"Antimicrob Agents Chemother"},{"issue":"9846","key":"4655_CR85","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/s0140-6736(12)61080-0","volume":"380","author":"AH Diacon","year":"2012","unstructured":"Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM (2012) 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380(9846):986. https:\/\/doi.org\/10.1016\/s0140-6736(12)61080-0","journal-title":"Lancet"},{"issue":"4","key":"4655_CR86","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/jac\/dkaa489","volume":"76","author":"S Tahseen","year":"2021","unstructured":"Tahseen S, Van Deun A, de Jong BC, Decroo T (2021) Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know? J Antimicrob Chemother 76(4):831\u20135. https:\/\/doi.org\/10.1093\/jac\/dkaa489","journal-title":"J Antimicrob Chemother"},{"issue":"10366","key":"4655_CR87","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","volume":"400","author":"RL Goodall","year":"2022","unstructured":"Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, Chiang CY, Conradie F, Gurumurthy M, Kirenga B, Kiria N (2022) Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet 400(10366):1858\u20131868. https:\/\/doi.org\/10.1016\/S0140-6736(22)02078-5","journal-title":"Lancet"},{"issue":"12","key":"4655_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00149-6","volume":"5","author":"ES Shaw","year":"2024","unstructured":"Shaw ES, Stoker NG, Potter JL, Claassen H, Leslie A, Tweed CD, Chiang CY, Conradie F, Esmail H, Lange C, Pinto L (2024) Bedaquiline: what might the future hold? Lancet Microbe 5(12):100909. https:\/\/doi.org\/10.1016\/S2666-5247(24)00149-6","journal-title":"Lancet Microbe"},{"issue":"8","key":"4655_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071119","volume":"8","author":"S Achanta","year":"2013","unstructured":"Achanta S, Jaju J, Kumar AM, Nagaraja SB, Shamrao SR, Bandi SK, Kumar A, Satyanarayana S, Harries AD, Nair SA, Dewan PK (2013) Tuberculosis management practices by private practitioners in Andhra Pradesh, India. PLoS One 8(8):e71119. https:\/\/doi.org\/10.1371\/journal.pone.0071119","journal-title":"PLoS One"},{"issue":"8","key":"4655_CR90","doi-asserted-by":"publisher","first-page":"e12023","DOI":"10.1371\/journal.pone.0012023","volume":"5","author":"ZF Udwadia","year":"2010","unstructured":"Udwadia ZF, Pinto LM, Uplekar MW (2010) Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades? PLoS One 5(8):e12023. https:\/\/doi.org\/10.1371\/journal.pone.0012023","journal-title":"PLoS One"},{"issue":"1","key":"4655_CR91","doi-asserted-by":"publisher","DOI":"10.3402\/iee.v3i0.23006","volume":"3","author":"SR Shrivastava","year":"2013","unstructured":"Shrivastava SR, Shrivastava PS, Ramasamy J (2013) Notification of tuberculosis cases in India: moving ahead in Revised National Tuberculosis Control Program. Infect Ecol Epidemiol 3(1):23006. https:\/\/doi.org\/10.3402\/iee.v3i0.23006","journal-title":"Infect Ecol Epidemiol"},{"key":"4655_CR92","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jgar.2020.02.029","volume":"2929","author":"D Sharma","year":"2020","unstructured":"Sharma D, Sharma S, Sharma J (2020) Potential strategies for the management of drug-resistant tuberculosis. J Glob Antimicrob Resist 2929:210\u2013214. https:\/\/doi.org\/10.1016\/j.jgar.2020.02.029","journal-title":"J Glob Antimicrob Resist"},{"issue":"38","key":"4655_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202406143","volume":"36","author":"H Wang","year":"2024","unstructured":"Wang H, Li B, Sun Y, Ma Q, Feng Y, Jia Y, Wang Wei, Su Min, Liu Xueting, Shu Bowen, Zheng Jundun, Sang Shuo, Yan Yan, Wu Yanqiu, Zhang Yunlong, Gao Qiuxia, Li Peiran, Wang Jiamei, Ma Fei, Li Xiaoxue, Yan Dingyuan, Wang Dong, Zou Xiaoming, Liao Y (2024) NIR-II AIE luminogen-based erythrocyte-like nanoparticles with granuloma-targeting and self-oxygenation characteristics for combined phototherapy of tuberculosis. Adv Mater 36(38):2406143. https:\/\/doi.org\/10.1002\/adma.202406143","journal-title":"Adv Mater"},{"issue":"11","key":"4655_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/jobm.70090","volume":"65","author":"D Sharma","year":"2025","unstructured":"Sharma D, Singh I, Sharma J, Verma IK, Ratn A (2025) Bacteriophage therapy to combat microbial infections and antimicrobial resistance. J Basic Microbiol e70090. https:\/\/doi.org\/10.1002\/jobm.70090","journal-title":"J Basic Microbiol"},{"key":"4655_CR95","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.imlet.2019.07.008","volume":"213","author":"E Chen","year":"2019","unstructured":"Chen E, Chen C, Chen F, Yu P, Lin L (2019) Positive association between MIC gene polymorphism and tuberculosis in Chinese population. Immunol Lett 213:62\u201369. https:\/\/doi.org\/10.1016\/j.imlet.2019.07.008","journal-title":"Immunol Lett"},{"key":"4655_CR96","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/IDR.S544665","volume":"18","author":"S Patil","year":"2025","unstructured":"Patil S, Singh I, Verma IK, Kumar A, Sharma J, Ratn A, Sharma D (2025) Vaccines as potential frontliners against antimicrobial resistance (AMR): a focused review. Infect Drug Resist 18:5023\u20135041. https:\/\/doi.org\/10.2147\/IDR.S544665","journal-title":"Infect Drug Resist"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-025-04655-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-025-04655-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-025-04655-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T13:15:40Z","timestamp":1770383740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-025-04655-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4655"],"URL":"https:\/\/doi.org\/10.1007\/s00284-025-04655-7","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"57"}}